Welcome to our dedicated page for InMode Ltd. Ordinary Shares news (Ticker: $INMD), a resource for investors and traders seeking the latest updates and insights on InMode Ltd. Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect InMode Ltd. Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of InMode Ltd. Ordinary Shares's position in the market.
Rhea-AI Summary
InMode Ltd. (Nasdaq: INMD) announced its Q3 2023 financial results. The company reported quarterly revenue of $123.1 million, a 2% increase compared to Q3 2022. InMode's proprietary surgical technology platforms accounted for 83% of revenues, followed by hands-free platforms at 9% and traditional laser and non-invasive RF platforms at 8%. The company's GAAP net income was $46.5 million, while non-GAAP net income was $53.1 million. Quarterly revenues from consumables and service reached $17.9 million, a 28% increase from Q3 2022. InMode's total cash position as of September 30, 2023, was $675.8 million, including cash, cash equivalents, marketable securities, and short-term bank deposits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.35%
Tags
-
Rhea-AI Summary
InMode files patent infringement complaint against BTL Industries
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
-
Rhea-AI Summary
InMode Ltd. expects to release its financial results for Q3 2023 on Nov. 2, 2023. Preliminary results suggest a downtick in platform sales due to economic slowdown and financing constraints. Revenue for Q3 2023 is expected to be in the range of $122.8 million to $123.0 million. Non-GAAP earnings per diluted share for Q3 2023 are expected to be in the range of $0.59 to $0.60. Revenue for the full year of 2023 is expected to be in the range of $500 million to $510 million. Non-GAAP gross margin for Q3 2023 is expected to be in the range of 83% to 85%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.97%
Tags
Rhea-AI Summary
InMode Ltd. addresses the status of its activity in Israel, assuring no interruption to production and prioritizing employee safety. Inventory levels are sufficient for the next three quarters. Revenues generated from Israel account for less than 1%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
-
Rhea-AI Summary
InMode Ltd. announces participation in investor conferences and events in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
-
Rhea-AI Summary
InMode Ltd. to participate in investor conferences and events in August.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
Rhea-AI Summary
InMode Ltd. (Nasdaq: INMD) announced its second quarter 2023 financial results, reporting a record quarterly revenue of $136.1 million, a 20% increase from the same period last year. The company's proprietary surgical technology platforms accounted for 81% of revenues, with a 44% increase in consumables and service revenues. InMode also reported a record GAAP net income of $55.7 million and a non-GAAP net income of $62.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
-
News
Rhea-AI Summary
InMode Ltd. (Nasdaq: INMD) has completed a significant IP transaction in the women's health and wellness market, acquiring all intellectual property assets of Viveve Medical Inc. This acquisition, along with an exclusive licensing agreement with the University of California, solidifies InMode's position as the global market leader in women's wellness products development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
-
Rhea-AI Summary
InMode Ltd., a global provider of medical technologies, will release its financial results for Q2 2023 on July 27, 2023. Preliminary results show expected revenue of $135.7 million to $135.9 million for Q2 2023, non-GAAP earnings per diluted share of $0.70 to $0.71, and full-year revenue guidance of $530 million to $540 million. The non-GAAP gross margin for Q2 2023 is expected to be in the range of 83% to 85%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11%
Tags
Rhea-AI Summary
InMode Ltd. announced their participation in several upcoming investor conferences and events. They will be presenting at the BNPP Exane Aesthetics Day, the Barclays West Coast Bus Trip, and the Jefferies Healthcare Conference. The presentations will be led by key executives including the CEO, CFO, and Chief Medical Officer. The events will include virtual fireside chats, in-person investor bus tours, and one-on-one meetings. Webcasts of the presentations will be available for replay and live access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
InMode Ltd. Ordinary Shares
Nasdaq:INMD
INMD Rankings
INMD Stock Data
1.55B
75.70M
9.69%
65.69%
6.98%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
United States of America
Yokne'am
About INMD
inmode offers the most exciting and effective aesthetic solutions with fractora, forma/plus, lumeccca, diolaze and bodyfx. fractora: bipolar radio-frequency fractional treatment for superior improvements in texture, wrinkles, acne scars and contraction. lumecca: broad spectrum pulsed light for rejuvenation of photo-damaged skin in a wide variety of skin types. diolaze: ultra fast diode hair removal featuring simultaneous 3pc (pre, parallel, and post cooling) technology and state of the art pulsing and power. bodyfx: non-invasive body contouring for buttocks, abdomen, flanks and thighs with a.c.e. technology